secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2021-09-29T23:59:59+00:00
Accession:  0000950170-21-001914
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns appoints former AstraZeneca CMO Ann Taylor to board
---------------------------------------------------------

- Ann E. Taylor, M.D. appointed as Class I director effective Sept 28, 2021.
- Dr. Taylor brings >35 years of drug development experience, including CMO of AstraZeneca.
- She will receive an initial option grant of 44,000 shares and $40k annual cash retainer.
- Her expertise in NASH and clinical development supports Terns' pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017021001914/0000950170-21-001914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017021001914/tern-20210928.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-001914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer